| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4003704 | American Journal of Ophthalmology | 2010 | 11 Pages |
Abstract
Ranibizumab provided significant VA benefit in patients with AMD-related CNV compared with sham injection. Ranibizumab appeared to provide additional VA benefit to treated patients who rolled over to monthly dosing, but not to patients who began receiving ranibizumab after >14 months of sham injections.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Prema Abraham, Huibin Yue, Laura Wilson,